

## 生物医学论文投稿、修回、校样及发表相关事宜 信件模板及实例

美捷登 编写

2022 年 3 月

请注意，本模板基于美捷登 2010 年版本进行更新，适用于绝大部分生物医学论文回复信件，

仅供参考，请以实际文稿情况为准。

版权所有，转贴请注明来源。

---

### **Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## Table of Contents

投稿信(Cover letter).....	1
催稿信(Reminder letter) .....	3
回复信(Reply/Response Letter) .....	4
申诉信(Appeal letter) .....	8
延时修回申请信(Request for extension of the deadline) .....	10
作者顺序更改信(Author Change Request Letter) .....	11
费用减免申请信(Concession Request Letter) .....	12
撤稿申请信(Withdrawal Request Letter).....	14
给作者全文索取信(Reprint Request Letter to Author) .....	15
作者职责、版权转让及利益冲突声明样本(Examples for Authors Responsibility and Copyright Transfer, Declaration of Conflict of Interest) .....	16
例一 Journal of Clinical Gastroenterology .....	16
例二 Cancer .....	17
例三 Gastroenterology .....	20
例四 Alimentary Pharmacology & Therapeutics .....	21
例五 Drug Safety .....	23
校样及单行本订单样本(Examples for Proofs and Reprint Order Form) .....	26
例一 Alimentary Pharmacology & Therapeutics .....	26
例二 Cancer .....	26

---

### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## 投稿信(Cover letter)

*(Please delete the annotations in italic in the parentheses.)*

---

Editorial Office,

XXXXXXX *(Address of the Editorial Office)*

March 21, 2022 *(for an American journal)*

21 March 2022 *(for a British or European Journal)*

Dear Editor,

We would like to submit an original (or a review) article entitled XXXX *(title of the article)* for consideration for publication in XXXX *(name of the journal)*.

*(You may use one paragraph to summarize the significance or merits of the present study here.)*

This article has not been published elsewhere in whole or in part. All authors have read and approved the content, and agree to submit it for consideration for publication in the journal. There are no ethical/legal conflicts involved in the article.

This manuscript has been edited and proofread by a professional editing service, Medjaden Inc.

Your consideration for this manuscript is highly appreciated.

Looking forward to hearing from you soon.

With kind regards,

Yours sincerely,

XXXX *(name of the corresponding author)*

---

### **Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

Professor of XXXX (*Department of the corresponding author*)

Telephone: XXXXX

E-mail: XXXXX

Corresponding author

---

**Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## 催稿信(Reminder letter)

*(Please delete the annotations in italic in the parentheses.)*

---

Dear Dr. or Prof. XXXX (*family name of the Editor or Editor-in-Chief who issued the decision letter*),

Re: Ms# XXXX (*number of the manuscript if any*) – XXXX (*title of the article*)

The abovementioned manuscript has been submitted (*or re-submitted*) for over X (*3 for submission, 2 for re-submission*) months, but I have not heard of any decision from the journal.

I will be most grateful if you could let me know the current status of the manuscript.

Please also advise if you need any additional information for the manuscript.

Thank you very much for your consideration, and look forward to hearing from you soon.

With kind regards,

Yours sincerely,

XXXX (*name of the corresponding author*)

Professor of XXXX (*Department of the corresponding author*)

Telephone: XXXXX

E-mail: XXXXX

Corresponding author

---

### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## 回复信(Reply/Response Letter)

*(Please delete the annotations in italic in the parentheses.)*

---

Dear Dr. or Prof. XXXX *(family name of the Editor or Editor-in-Chief who issued the decision letter)*,

Thank you very much for your letter and advice. We have revised the manuscript and would like to resubmit it for your consideration. We have addressed the comments raised by the reviewers, and the amendments are highlighted in red in the revised manuscript. Point-by-point responses to the reviewers' comments are listed below this letter.

This revised manuscript has been edited and proofread by a professional editing service, *Medjaden Inc.*

We hope that the revised version of the manuscript is now acceptable for publication in your journal.

I look forward to hearing from you soon.

With best wishes,

Yours sincerely,

XXXX *(name of the corresponding author)*

Professor of XXXX *(Department of the corresponding author)*

Telephone: XXXXX

E-mail: XXXXX

Corresponding author

---

### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

## Replies to Reviewer

We would like to express our sincere thanks to the reviewers for the constructive and positive comments.

## Replies to Reviewer 1

### Specific Comments

1. JNK2 mRNA levels are relatively higher in SW1116 cells, COLO205 and AGS cells, when compared to the other cell lines tested. However, Similarly JNK proteins levels are high in the three cell lines. However, is low in SW1116 cells, compared to the other two. In addition, the SP compound induced higher levels of apoptosis in AGS and COLO205 cells. It seems that inhibition of phosphorylated JNK may be the mechanism by which the SP compound is acting in these cells. The authors should discuss this potential possibility in the Discussion section.

Answer: Several sentences have been changed in the Discussion (page 12, paragraph 1) in the revised version to address this issue.

2. The author should mention why they chose the six cell lines for their study.

Answer: AGS, HT-29 and COLO205 are widely used gastrointestinal cell lines for MAPK pathway study. And the rest three cell lines are commonly investigated in our Lab.

3. Surprisingly, inhibition of MKN-45 cell proliferation did not occur until 72 h. Could this be due to the slower growth of the cells in the first place?

Answer: Actually, we didn't find MKN-45 cell grow obviously slower than the other cell lines in our study.

4. In the studies with the caspase inhibitor, the authors have only mentioned their results in COLO205. It would be expected that a similar result would have been obtained for AGS cells as well. If so, for the sake of completeness of the report they could add a line stating so.

Answer: The statement of AGS has been added in Results (page 10, paragraph 1, line 4) in the revised version.

### Additional Minor Comments:

---

#### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

## Materials and Methods

a. 2.1 Cell cultures. In the first line, MKN-45 cell line is not stated.

**Answer: MKN-45 has been added in the revised version.**

b. 2.4 Detection of Caspase-3 activity- typographical error -pH (line 10)

**Answer: Correction has been made in the revised version.**

## Results

First-line- page 10 typographical error- caspase-9

**Answer: Correction has been made in the revised version (page 10, paragraph 1, line 7).**

## References

a. In ref 6, there is a typographical error, the year is not bracketed and volume is switched.

**Answer: Correction has been made in the revised version.**

b. In ref 23. There is a space after journal name.

**Answer: Correction has been made in the revised version (ref 24).**

## Replies to Reviewer 2

Minor considerations:

1. Can the authors describe clearly the relations between phosphorylated JNK p38 p54, p56 and JNK1 and JNK2, and the significance of their expression?

**Answer: Several sentences have been added in the Introduction (page 3, paragraph 1) and Results (page 8, paragraph 3 and page 9, paragraph 1) in the revised version to address this issue.**

2. The experiments are extensive in the present study. However, the author may wish to perform a further functional study to prove that the differential response in cells to SP-600125 is associated with their basal JNK2 expression.

---

### Disclaimer

*The templates are prepared by Medjaden Inc. (www.medjaden.com, medjaden@gmail.com) as references, for our fellow Chinese investigators to publish their research articles in English journals. Medjaden encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. Medjaden is not responsible, in any way, for any negative decision made by the journals.*



---

Answer: Yes, the further functional study will be conducted to prove the correlation between basal JNK2 expression and cell response to SP-600125, e.g. transfection of JNK2 siRNA or antisense.

3. There appear some illegal symbols, such as "20?", 37?, etc" in the Methods section.

Answer: Corrections have been made in the revised version.

4. It is unclear why the author chose to use the dose of 20uM of SP-600125 for treatment of all cancer cell lines. It is recommended that the authors show a dose-response curve for the different cell lines.

Answer: Hideshima T et. al. state in their paper "Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines" that SP600125 inhibits cell growth in a dosage-dependent manner (2.5~20uM) in myeloma cell lines. SP600125 20uM in our experiment was found to effectively exert its inhibitory effect without cytotoxicity. This reference has been quoted as ref.16 in the revised version.

5. Figure 3 would be improved by including the distribution of all phases of the cell cycle (e.g. G0/G1, G2/M and S phase).

Answer: The phases of the cell cycle distribution of AGS and COLO205, the two most responsive cell lines with or without treatments, have been listed in Table-1. The G2/M arrest data have been highlighted.

6. The results of apoptosis should be included in table 1.

Answer: Since apoptosis is not routinely assessed by single PI staining, we used double staining with Annexin V and PI to detect apoptosis more sensitively. The result was shown in Fig.3.

7. Page 11 line 5, "SP-600125 induced 1.5-4.5 more times apoptotic cells in 4 out of 6 cancer cell lines". The authors should be more specific and provide the raw data for all the cell lines in the results section.

Answer: Several sentences have been added in the Results (page 9, paragraph 3; page 10, paragraph 1) to address this issue.

---

#### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## 申诉信(Appeal letter)

*(Please delete the annotations in italic in the parentheses.)*

---

Dear Dr. or Prof. XXXX *(family name of the Editor or Editor-in-Chief who issued the decision letter)*,

Thank you for your efficient work in processing our manuscript entitled XXXX *(title of the article)* (Manuscript No: XXXX).

After we have carefully read the comments of the reviewers, we realize that the major merits of our work were not fully identified or recognized by the reviewers, mainly due to our unclear descriptions in the original manuscript. *(If one or more reviewers pointed out the merits of the study, but criticized the language and presentation of the manuscript, then you should state that: After we have carefully read the comments of the reviewers, we realize that although the reviews identified or recognized the major merits of our work, our manuscript was poorly prepared, which, we believe, can be improved by a native speaker or a professional editing company.)*

Here we would emphasize that the most notable merits of our manuscript include:

- 1)
- 2)
- 3)
- ...

We thank the reviewers for their critical and constructive comments and suggestions. Enclosed below this letter are our point-by-point responses to the comments. In addition, we have extensively revised the manuscript in response to the comments, and the amendments are highlighted in red in the revised manuscript.

The revised manuscript has been edited and proofread by a professional editing service, *Medjaden Inc.*

I will be most grateful if you could offer us a second opportunity *(or an additional opportunity if the rejected manuscript is already a revised one)*.

Look forward to hearing from you soon,

---

### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

With kind regards,

Yours sincerely,

XXXX (*name of the corresponding author*)

Professor of XXXXX (*Department of the corresponding author*)

Telephone: XXXXX

E-mail: XXXXX

Corresponding author

### **Replies to reviewers**

We would like to express our sincere thanks to the reviewers for the critical, constructive and positive comments and suggestions.

Replies to Reviewer 1

XXXX (*Point by point responses to the comments of reviewer 1*).

Replies to Reviewer 2

XXXX (*Point by point responses to the comments of reviewer 2*).

---

#### **Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## 延时修回申请信(Request for extension of the deadline)

*(Please delete the annotations in italic in the parentheses.)*

---

Dear Dr. or Prof. XXXX *(family name of the Editor or Editor-in-Chief who issued the decision letter)*,

I am writing you regarding our submitted article entitled XXXX *(title of the article)* (Manuscript No: XXXX), which is currently under revision.

Due to my business trip and an annual leave afterward, I did not read the messages from your editorial office on time. *(Or you may have other reasons that may delay the revision process and you should make a statement accordingly).*

Since major revisions are needed for our manuscript, I am afraid that we are not able to resubmit the revised version of the manuscript by the deadline *(the date of the current deadline)*.

Therefore, I will be most grateful if you could extend the deadline, preferably, for 2 weeks *(or any duration you wish to extend, but better less than 1 month if possible)*, so that we can revise the manuscript more appropriately.

Thank you in advance for your understanding and kind assistance, and look forward to receiving your advice soon.

With kind regards,

Yours sincerely,

XXXX *(name of the corresponding author)*

Professor of XXXXX *(Department of the corresponding author)*

Telephone: XXXXX

E-mail: XXXXX

Corresponding author

---

### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## 作者顺序更改信(Author Change Request Letter)

*(Please delete the annotations in italic in the parentheses.)*

---

Dear Dr. or Prof. XXXX *(family name of the Editor or Editor-in-Chief who issued the decision letter)*,

Re: Ms# XXXX *(number of the manuscript if any)* – XXXX *(title of the article)*

I am writing you to make a change in the order of the authors. We wish to place Dr. XXX in the second place *(or wherever you wish)*. All others have agreed with this change.

We hope that this change is acceptable. However, please advise if you have any questions about this change.

Thank you very much for your consideration.

With kind regards,

Yours sincerely,

XXXX *(name of the corresponding author)*

Professor of XXXXX *(Department of the corresponding author)*

Telephone: XXXXX

E-mail: XXXXX

Corresponding author

---

### **Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## 费用减免申请信(Concession Request Letter)

*(Please delete the annotations in italic in the parentheses.)*

---

Dear Dr. or Prof. XXXX *(family name of the Editor or Editor-in-Chief who issued the decision letter)*,

Re: Ms# XXXX *(number of the manuscript if any)* – XXXX *(title of the article)*

I am very pleased that our paper has been accepted for publication in XXX *(name of the journal)*.

We notice that there is a charge for the publication of the manuscript *(or for printing the color figures, or whatever you are charged)*. The publication fees *(or costs for printing the color figures, or whatever you are charged)* appear too expensive for us at the moment. Although this project was supported by a grant from \*\*\*\*, the total amount of the grant was RMBXXXX *(about \$XXXX)*, with which we just managed to conduct and complete our experiments, and thus we do not have enough funding to pay for the publication fees *(or for printing the color figures, or whatever you are charged)*.

Therefore, I am writing you to explore the possibility that the publication fees *(or for printing the color figures, or whatever you are charged)* could be reduced or even waived. However, if you cannot offer us such a concession, we will make our every effort to make the payment of the publication fees *(or for printing the color figures, or whatever you are charged)* as the publication of this paper in your journal is very important for us.

Thanks very much for your consideration, and look forward to hearing from you soon.

With kind regards,

Yours sincerely,

XXXX *(name of the corresponding author)*

Professor of XXXXX *(Department of the corresponding author)*

---

### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

Telephone: XXXXX

E-mail: XXXXX

Corresponding author

---

**Disclaimer**

*The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.*

---

## 撤稿申请信(Withdrawal Request Letter)

*(Please delete the annotations in italic in the parentheses.)*

---

Dear Dr. or Prof. XXXX *(family name of the Editor or Editor-in-Chief who issued the decision letter)*,

Re: Ms# XXXX *(number of the manuscript if any)* – XXXX *(title of the article)*

I am writing you to inform you that we have to withdraw the abovementioned manuscript for further consideration for publication in XXXX *(journal's name)*, due to a technical reason *(or whatever a reason that is convincing)*.

I apologize for any inconvenience caused by the withdrawal of this article.

Once again, thank you very much for your consideration and time.

With kind regards,

Yours sincerely,

XXXX *(name of the corresponding author)*

Professor of XXXXX *(Department of the corresponding author)*

Telephone: XXXXX

E-mail: XXXXX

Corresponding author

---

### **Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.



---

## 给作者全文索取信(Reprint Request Letter to Author)

*(Please delete the annotations in italic in the parentheses.)*

---

Dear Dr. or Prof. XXXX *(family name of the Editor or Editor-in-Chief who issued the decision letter)*,

I am very interested in reading your article published in XXXX *(name of the journal)* *(the full citation copied from PubMed or other data source)*.

However, our library does not subscribe to the journal. Therefore, I am writing to you to request if you could send me the reprint in pdf, or a copy of the article by email, or by postal mail. I will be also grateful if you could send all your articles relevant to the topic *(add this sentence only if you really need it)*.

Thank you very much in advance.

With kind regards,

Yours sincerely,

XXXX *(name of the corresponding author)*

Professor of XXXXXX *(Department of the corresponding author)*

Telephone: XXXXXX

E-mail: XXXXXX

Corresponding author

---

### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

## 作者职责、版权转让及利益冲突声明样本(Examples for Authors Responsibility and Copyright Transfer, Declaration of Conflict of Interest)

例一 *Journal of Clinical Gastroenterology*

### **Journal of Clinical Gastroenterology** Authorship Responsibility, Financial Disclosure, and Copyright Transfer

**Manuscript Title: (the "Work")** Quality of Life and Psychological Impact in Patients with Non-cardiac Chest Pain

**Corresponding Author:** Benjamin CY Wong

**Mailing Address and Telephone/Fax Numbers:** Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. Tel No:(852) 2855-4542. Fax No:(852) 2872-5828

Each author must read and sign the following statements; if necessary, photocopy this document and distribute to coauthors for their original ink signatures. Completed forms should be submitted to the Editorial Office with the Work or returned to: Martin H. Floch, MD, Clinical Professor of Medicine, Yale University School of Medicine, Section of Digestive Diseases, P.O. Box 208019, 333 Cedar Street, LMP 1080, New Haven, CT 06520.

#### **CONDITIONS OF SUBMISSION**

**RETAINED RIGHTS:** Except for copyright, other proprietary rights related to the Work shall be retained by the authors. To reproduce any text, figures, tables, or illustrations from this Work in future works of their own, the authors must obtain written permission from Lippincott Williams & Wilkins (LWW); such permission cannot be unreasonably withheld by LWW.

**ORIGINALITY:** Each author warrants that his or her submission to the Work is original and that he or she has full power to enter into this agreement. Neither this Work nor a similar work has been published nor shall be submitted for publication elsewhere while under consideration by this Publication.

**AUTHORSHIP RESPONSIBILITY:** Each author certifies that he or she has participated sufficiently in the intellectual content, the analysis of data, if applicable, and the writing of the Work to take public responsibility for it. Each has reviewed the final version of the Work, believes it represents valid work, and approves it for publication. Moreover, should the editors of the Publication request the data upon which the work is based, they shall produce it.

**DISCLAIMER:** Each author warrants that this Work contains no libelous or unlawful statements and does not infringe on the rights of others. If excerpts (text, figures, tables, or illustrations) from copyrighted works are included, a written release will be secured by the authors prior to submission, and credit to the original publication will be properly acknowledged. Each author warrants that he or she has obtained, prior to submission, written releases from patients whose names or photographs are submitted as part of the Work. Should LWW request copies of such written releases, authors shall provide them to LWW in a timely manner.

#### **TRANSFER OF COPYRIGHT**


**AUTHORS' OWN WORK:** In consideration of LWW's publication of the Work, the authors hereby transfer, assign, and otherwise convey all copyright ownership worldwide, in all languages, and in all forms of media now or hereafter known, including electronic media such as CD-ROM, Internet, and Intranet, to LWW. If LWW should decide for any reason not to publish an author's submission to the Work, LWW shall give prompt notice of its decision to the corresponding author; this agreement shall terminate, and neither the author nor LWW shall be under any further liability or obligation. The authors grant LWW the rights to use their names and biographical data (including professional affiliation) in the Work and in its or the Publication's promotion.

**WORK MADE FOR HIRE:** If this work has been commissioned by another person or organization, or if it has been written as part of the duties of an employee, an authorized representative of the commissioning organization or employer must also sign this form stating his or her title in the organization.

**GOVERNMENT EMPLOYEES:** If this submission to the Work has been written in the course of the author's employment by the United States Government, check the "Government" box at the end of this form. A work prepared by a government employee as part of his or her official duties is called a "work of the U.S. Government" and is not subject to copyright. If it is not prepared as part of the employee's official duties, it may be subject to copyright.

**FINANCIAL DISCLOSURE:** Each author certifies that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article, except as disclosed on a separate attachment. All funding sources supporting the Work and all institutional or corporate affiliations of the authors are acknowledged in a footnote in the Work.

**INSTITUTIONAL REVIEW BOARD/ANIMAL CARE COMMITTEE APPROVAL:** Each author certifies that his or her institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.

	Harry H.X. Xia	July 16, 2007
Signature	Printed Name	Date
<input type="checkbox"/> Author's Own Work	<input type="checkbox"/> Work for Hire	<input type="checkbox"/> Government
		<input type="checkbox"/> Financial Disclosure Attached
Signature	Printed Name	Date
<input type="checkbox"/> Author's Own Work	<input type="checkbox"/> Work for Hire	<input type="checkbox"/> Government
		<input type="checkbox"/> Financial Disclosure Attached
Signature	Printed Name	Date
<input type="checkbox"/> Author's Own Work	<input type="checkbox"/> Work for Hire	<input type="checkbox"/> Government
		<input type="checkbox"/> Financial Disclosure Attached
Signature	Printed Name	Date
<input type="checkbox"/> Author's Own Work	<input type="checkbox"/> Work for Hire	<input type="checkbox"/> Government
		<input type="checkbox"/> Financial Disclosure Attached

#### **Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

例二 Cancer

From Henry H-X Xian  
Total PAGES: 2

Cancer: A JOURNAL OF THE AMERICAN CANCER SOCIETY, INC.

**AUTHORSHIP RESPONSIBILITY, COPYRIGHT TRANSFER AND FINANCIAL DISCLOSURE**

Manuscript Number (example C-0000-08): C-2732-08  
Manuscript Title: Serum macrophage migration inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer  
Corresponding Author's Name: Dr. B.C.Y. Wong Telephone Number: +852-38354541  
Address: Department of Medicine, Facsimile Number: +852-29049443  
Queen Mary Hospital E-mail Address: beywong@hku.hk  
The University of Hong Kong, HONG KONG

By signing in the space provided at the end of this document, each author affirms that he/she has read and agrees to the following:  
(1) authorship responsibility; (2) copyright transfer; and (3) financial disclosure. If necessary, photocopy or email this document and distribute to each author for his/her original ink signature. Please compile all forms and send to:

CANCER Editorial Office  
American Cancer Society  
250 Williams Street  
Atlanta, GA 30303  
USA  
Fax: (404) 551-5650

Please be sure that the form is filled out completely and is legible.

**1. Authorship Responsibility:** By signing this document, I certify that I have participated sufficiently in the conception and design of this work, the analysis of the data (where applicable), as well as the writing of the manuscript, to take public responsibility for it. I represent to the best of my knowledge that the manuscript represents our valid original work. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as a corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by *CANCER*, except for "preprints" as permitted below, except as described in an attachment. Furthermore, I attest that I shall produce the data on which the manuscript is based for examination by the editors or their assignees should they request it. The undersigned author(s) also represent to the best of their knowledge that this work contains no libelous or unlawful statements, does not infringe on the rights of others, or contain material or instructions that might cause harm or injury.

**2. COPYRIGHT TRANSFER AGREEMENT:**

**A. COPYRIGHT**

1. The author assigns to the American Cancer Society, Inc., during the full term of copyright and any extensions or renewals of that term, all copyright in and to the work, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the work and the material contained therein in electronic and print editions of *CANCER* and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.
2. Reproduction, posting, transmission or other distribution or use of the work or any material contained therein, in any medium as permitted hereunder, requires a citation to *CANCER* and an appropriate credit to Wiley-Liss, Inc. as Publisher, suitable in form and content as follows: (Title of Article, Author, *CANCER* and Volume/Issue Copyright © [year] American Cancer Society, Inc., or copyright owner as specified in *CANCER*.)

A7

**Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.



#### B. RETAINED RIGHTS

Notwithstanding the above, the author or, if applicable, the author's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the work, and the right to make oral presentations of material from the work.

#### C. OTHER RIGHTS OF AUTHOR

The American Cancer Society, Inc. grants back to the author the following:

1. The right to share with colleagues print or electronic "preprints" of the unpublished work, in form and content as accepted by the Publisher, Wiley-Liss, Inc., for publication in *CANCER*. Such preprints may be posted as electronic files on the author's own website for personal or professional use, or on the author's internal university or corporate networks/intranet, or secure external website at the author's institution, but not for commercial sale or for any systematic external distribution by a third party (e.g., a listserve or database connected to a public access server). Prior to publication, the author must include the following notice on the preprint: "This is a preprint of an article accepted for publication in *CANCER* Copyright © (year) American Cancer Society, Inc." After publication of the work by Wiley-Liss, Inc., the preprint notice should be amended to read as follows: "This is a preprint of an article published in [include the complete citation information for the final version of the work as published in the print edition of *CANCER*]", and should provide an electronic link to *CANCER*'s website, located at the following Wiley-Liss, Inc. URL: <http://www.interscience.wiley.com/canceronline>. The author agrees not to update the preprint or replace it with the published version of the work.
2. The right, without charge, to photocopy or to transmit online or to download, print out and distribute to a colleague a copy of the published work in whole or in part, for the author's personal or professional use, for the advancement of scholarly or scientific research or study, or for corporate informational purposes in accordance with Paragraph D.2 below.
3. The right to republish, without charge, in print format, all or part of the material from the published work in a book written or edited by the author.
4. The right to use selected figures and tables, and selected text (up to 250 words, exclusive of the abstract) from the work, for the author's own teaching purposes, or for incorporation within another work by the author that is made part of an edited work published (in print or electronic format) by a third party, or for presentation in electronic format on an internal computer network or external website of the author or the author's employer.
5. The right to include the work in a compilation for classroom use (course packs) to be distributed to students at the author's institution free of charge or to be stored in electronic format in datarooms for access by students at the author's institution as part of their course work (sometimes called "electronic reserve rooms") and for in-house training programs at the author's employer.

#### D. WORKS OWNED BY EMPLOYER

1. If the work was written by the author in the course of the author's employment (as a "work-made-for-hire" in the course of employment), the work is owned by the company/employer which must sign this Agreement (in addition to the author's signature), in the space provided below. In such case, the company/employer hereby assigns to the American Cancer Society, Inc. during the full term of copyright, all copyright in and to the work for the full term of copyright throughout the world as specified in paragraph A above.
2. In addition to the rights specified as retained in paragraph B above and the rights granted back to the author pursuant to paragraph C above, the American Cancer Society, Inc. hereby grants back, without charge, to such company/employer, its subsidiaries and divisions, the right to make copies of and distribute the published work internally in print format or electronically on the company's internal network. Upon payment of Wiley-Liss, Inc.'s reprint fee, the institution may distribute (but not resell) print copies of the published work externally. Although copies so made shall not be available for individual re-sale, they may be included by the company/employer as part of an information package included with software or other products offered for sale or license. Posting of the published work by the institution on a public access website may only be done with Wiley-Liss, Inc.'s written permission, and payment of any applicable fee(s).

#### E. GOVERNMENT CONTRACTS

In the case of a work prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the work and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S., U.K. Government Employees: see note at end).

- F. NIH FUNDED RESEARCH:** Wiley-Blackwell will post the accepted version of articles by NIH grant-holders to PubMed Central upon acceptance by the journal on the authors' behalf. This accepted version will be made publicly available 12 months after publication. The NIH mandate applies to all articles based on research that has been wholly or partially funded by the NIH and that are accepted for publication on or after April 7, 2008.

#### G. COPYRIGHT NOTICE

The author and the company/employer agree that any and all copies of the work or any part thereof distributed or posted by them in print or electronic format as permitted herein will include the notice of copyright as stipulated in *CANCER* and a full citation to *CANCER* as published by Wiley-Liss, Inc.

A8

---

#### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

The author(s) and the company/employer agree that any and all copies of this work or any part thereof published under the terms set forth above will include a notice of copyright in the name of the American Cancer Society, Inc. and a citation to *CANCER*.

☐ U.S. Government work

**Note to U.S. Government Employees:** A work prepared by a U.S. federal government employee as part of the employee's official duties is called a "U.S. Government work," and is in the public domain in the United States. In such cases, Section 2 of this form does not apply. Outside the U.S., Wiley-Liss Inc. may secure copyright to the extent authorized under the domestic laws of those foreign countries, subject to a paid-up, nonexclusive, irrevocable worldwide license to the U.S. Government in such copyrighted work to reproduce, prepare derivative works, distribute copies to the public and perform publicly and display publicly the work, and to permit others to do so. If this work was not prepared as part of the employee's duties, it is not a U.S. Government work.

☐ U.K. Government work (Crown Copyright)

**Note to U.K. Government Employees:** The rights in a work prepared by an employee of a U.K. government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. In such case, the Publisher will forward the relevant form to the employee for signature.

**3. Financial Disclosure:** By signing this document, I certify that any affiliations with or involvement (either competitive or amiable) in any organization or entity with a direct financial interest in the subject matter or materials discussed in the manuscript are noted below (e.g., employment, consultancies, stock ownership, honoraria, expert testimony, patent applications and/or ownership, etc.). Otherwise, my signature indicates that I have no such financial interest. All financial research or project support is identified in an acknowledgment in the manuscript. Any disclosures listed below must also appear on the first page of the manuscript.

**Statement of Financial Interest for All Authors:** (If more space is needed, submit a signed attachment) \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Manuscript number: C-2732-08

Author Signature

Date

Clearly Print Name

Hua X 4/29/2009 Harry Hua-Xiang Xia

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

A9

#### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.



### 例三 Gastroenterology

#### Copyright Assignment, Authorship Responsibility, NIH Funding, Financial Disclosure, Institutional Review Board/Animal Care Committee Approval, and Sponsorship

**Copyright Assignment.** In consideration of the American Gastroenterological Association (AGA) Institute (the "AGA Institute") taking action to review and credit the below-identified submission (the "Manuscript"), and for other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned authors and/or creators (the "Authors"), jointly and severally, hereby transfer, convey, and assign to the AGA Institute, free and clear of any liens, licenses or encumbrances, the entire right, title, and interest in and to the Manuscript throughout the world, including without limitation in and to any and all copyrights for the Manuscript (including but not limited to rights to copy, publish, excerpt, collect royalties and make derivative works) in print, electronic, Internet, broadcast, and all other forms and media now or hereafter known, and for any and all causes of action heretofore accrued in Authors' favor for infringement of the aforesaid copyrights, to have and to hold the same unto the AGA Institute, its successors and assigns, for and during the existence of the aforesaid copyrights, and all renewals and extensions thereof. At any time and from time to time hereafter, the Authors shall upon the AGA Institute's written request take any and all steps and execute, acknowledge and deliver to the AGA Institute any and all further instruments and assurances necessary or expedient in order to vest the aforesaid copyrights and causes of action more effectively in the AGA Institute. The Authors retain the nonexclusive permission to use all or part of the Manuscript in future works of their own in a noncompeting way, provided proper copyright credit is given to the AGA Institute. Should the AGA Institute finally determine that it will not publish the Manuscript, the AGA Institute agrees to assign its rights therein back to the Authors.

**Authorship Responsibility.** I, the undersigned Author, certify that I have participated sufficiently in the intellectual content, the analysis of data, if applicable, and the writing of the Manuscript, to take public responsibility for it. I have reviewed the final version of the Manuscript, believe it represents valid work, and approve it for publication. As an Author of this Manuscript, I certify that, except to the extent expressly credited to others in the text of the Manuscript: the entire Manuscript is an original creation of the Authors; and none of the material in the Manuscript has been published previously, is included in another manuscript, or is currently under consideration for publication elsewhere. I also certify that this Manuscript has not been accepted for publication elsewhere, and that I have not assigned, licensed, or otherwise transferred any right or interest in the Manuscript to anyone. Moreover, should the AGA Institute or the editors of GASTROENTEROLOGY request the data upon which the Manuscript is based, I shall produce it. Authors are responsible for applying for permission for both print and electronic rights for all borrowed materials and are responsible for paying any fees related to the applications of these permissions.

**Institutional Review Board/Animal Care Committee Approval.** I, the undersigned Author, certify that my institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.

**Sponsorship.** I, the undersigned author, certify that I had full access to all of the data in this study, and I take responsibility for the integrity of the data and the accuracy of the data analysis.

Manuscript title: \_\_\_\_\_

Signatures: Each Author must sign and date this statement and assignment. In the case of a work made for hire, the employer(s) must also sign. For example, for any Manuscript including any portion created in the course of employment for another (whether as a regular employee or as an independent contractor) requires the signature of the relevant employer(s).

<p>_____</p> <p>Print Name: <u>Harry Hua Xiang Xia</u> Date: <u>04 Jun 08</u></p> <p>_____</p> <p>Print Name: _____ Date: _____</p> <p>_____</p> <p>Print Name: _____ Date: _____</p> <p>_____</p> <p>Print Name: _____ Date: _____</p> <p>Employer signature(s) as Author (required for works made for hire): _____</p> <p>(Employer) _____</p> <p>By: _____</p> <p>Print Name: _____ Date: _____</p>	<p>_____</p> <p>Print Name: _____ Date: _____</p> <p>_____</p> <p>Print Name: _____ Date: _____</p> <p>_____</p> <p>Print Name: _____ Date: _____</p> <p>_____</p> <p>Print Name: _____ Date: _____</p> <p>Employer signature(s) as Author (required for works made for hire): _____</p> <p>(Employer) _____</p> <p>By: _____</p> <p>Print Name: _____ Date: _____</p>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

☐ If this Manuscript exists in the public domain because it was written as part of the official duties of the Authors as employees of the U.S. government, check this box.

**National Institutes of Health (NIH) Funding.** My manuscript was supported in part, or in whole, by the NIH. In accordance with the NIH Public Access Policy, I would like to request that my manuscript, should it be accepted for publication, be submitted to PubMed Central (PMC). I understand that my manuscript will therefore be freely accessible by the public via PMC twelve months from the date of its publication.

☐ I would like my manuscript automatically submitted to PMC, should it ultimately be accepted. My NIH grant number is \_\_\_\_\_

**Financial Disclosure.** Check the appropriate box and sign where indicated. All Authors must sign one of the statements below.

☒ I, the undersigned Author, certify that I have no financial arrangements (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, research support, major honoraria, etc.) with a company whose product figures prominently in the submitted manuscript or with a company making a competing product except as disclosed on a separate attachment. All funding sources supporting the work are acknowledged on the title page.

\_\_\_\_\_

\_\_\_\_\_

☐ I, the undersigned Author, certify that I have included on the title page of the manuscript any financial arrangements (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, research support, major honoraria, etc.) that I have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. All funding sources supporting the work are acknowledged on the title page.

\_\_\_\_\_

\_\_\_\_\_

#### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.



例四 Alimentary Pharmacology & Therapeutics

Fax: +44 1438 814758  
APT Office



ALIMENTARY PHARMACOLOGY & THERAPEUTICS: Exclusive Licence Form

Author's name: Harry Hua-Xiang Xia  
Author's address: One Health Plaza, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07033 USA  
Title of article ("Article"): "True" Reinfection of Helicobacter pylori after successful eradication  
Manuscript no. (if known): APT-0723-2008  
Names of all authors in the order in which they appear in the Article: Yuanxun Zhang, Harry Xia, Zehao Zhuang, Jiang Zhong

In order for your Article to be distributed as widely as possible in *Alimentary Pharmacology & Therapeutics* (the Journal), you grant Blackwell Publishing Ltd. (Blackwell Publishing) an exclusive licence to publish the above Article, including the abstract in printed and electronic form, in all languages, and to administer subsidiary rights agreements with third parties for the full period of copyright and all renewals, extensions, revisions and revivals. The Article is deemed to include all material submitted for publication with the exception of Letters, and includes the text, figures, tables, author contact details and all supplementary material accompanying the Article.

Please read this form carefully, sign at the bottom (if your employer owns copyright in your work, arrange for your employer to sign where marked), and return the ORIGINAL to the address below as quickly as possible. As author, you remain the copyright owner of the Article, unless copyright is owned by your employer. (US Federal Government authors please note: your Article is in the public domain.)

Your Article will not be published unless an Exclusive Licence Form has been signed and received by Blackwell Publishing.

Please note: You retain the following rights to re-use the Article, as long as you do not sell or reproduce the Article or any part of it for commercial purposes (i.e. for monetary gain on your own account or on that of a third party, or for indirect financial gain by a commercial entity). These rights apply without needing to seek permission from Blackwell Publishing.

- **Prior to acceptance:** We ask that as part of the publishing process you acknowledge that the Article has been submitted to the Journal. You will not prejudice acceptance if you use the unpublished Article, in form and content as submitted for publication in the Journal, in the following ways:
    - sharing print or electronic copies of the Article with colleagues;
    - posting an electronic version of the Article on your own personal website, on your employer's website/repository and on free public servers in your subject area.
  - **After acceptance:** Provided that you give appropriate acknowledgement to the Journal and Blackwell Publishing, and full bibliographic reference for the Article when it is published, you may use the accepted version of the Article as originally submitted for publication in the Journal, and updated to include any amendments made after peer review, in the following ways:
    - you may share print or electronic copies of the Article with colleagues;
    - you may use all or part of the Article and abstract, without revision or modification, in personal compilations or other publications of your own work;
    - you may use the Article within your employer's institution or company for educational or research purposes, including use in course packs;
    - 12 months after publication you may post an electronic version of the Article on your own personal website, on your employer's website/repository and on free public servers in your subject area.
- Electronic versions of the accepted Article must include a link to the published version of the Article together with the following text: 'The definitive version is available at [www.blackwell-synergy.com](http://www.blackwell-synergy.com)'.

Please note that you are not permitted to post the Blackwell Publishing PDF version of the Article online.

All requests by third parties to re-use the Article in whole or in part will be handled by Blackwell Publishing. Any permission fees will be retained by the Journal. All requests to adapt substantial parts of the Article in another publication (including publication by Blackwell Publishing) will be subject to your approval (which is deemed to be given if we have not heard from you within 4 weeks of your approval being sought by us writing to you at your last notified address). Please address any queries to [journalsrights@oxon.blackwellpublishing.com](mailto:journalsrights@oxon.blackwellpublishing.com).

In signing this Agreement:

1. You hereby warrant that this Article is an original work, has not been published before and is not being considered for publication elsewhere in its final form either in printed or electronic form;
2. You hereby warrant that you have obtained permission from the copyright holder to reproduce in the Article (in all media including print and electronic form) material not owned by you, and that you have acknowledged the source;

26 May 2005

**Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.





3. You hereby warrant that this Article contains no violation of any existing copyright or other third party right or any material of an obscene, indecent, libellous or otherwise unlawful nature and that to the best of your knowledge this Article does not infringe the rights of others;
4. You hereby warrant that in the case of a multi-authored Article you have obtained, in writing, authorization to enter into this Agreement on their behalf and that all co-authors have read and agreed the terms of this Agreement;
5. You warrant that any formula or dosage given is accurate and will not if properly followed injure any person;
6. You will indemnify and keep indemnified the Editors and Blackwell Publishing against all claims and expenses (including legal costs and expenses) arising from any breach of this warranty and the other warranties on your behalf in this Agreement.

By signing this Agreement you agree that Blackwell Publishing may arrange for the Article to be:

- Published in the above Journal, and sold or distributed, on its own, or with other related material;
- Published in multi-contributor book form or other edited compilations by Blackwell Publishing;
- Reproduced and/or distributed (including the abstract) throughout the world in printed, electronic or any other medium whether now known or hereafter devised, in all languages, and to authorize third parties (including Reproduction Rights Organizations) to do the same;
- You agree to Blackwell Publishing using any images from the Article on the cover of the Journal, and in any marketing material.

You authorize Blackwell Publishing to act on your behalf to defend the copyright in the Article if anyone should infringe it, although there is no obligation on Blackwell Publishing to act in this way.

As the Author, copyright in the Article remains in your name (or your employer's name if your employer owns copyright in your work).

Blackwell Publishing undertakes that every copy of the Article published by Blackwell Publishing will include the full bibliographic reference for your Article, together with the copyright statement.

☒ **BOX A: to be completed if copyright belongs to you**

☐ **BOX B: to be completed if copyright belongs to your employer (e.g. HMSO, CSIRO)**

The copyright holder grants Blackwell Publishing an exclusive licence to publish the Article including the abstract in printed and electronic form, in all languages, and to administer subsidiary rights agreements with third parties for the full period of copyright and all renewals, extensions, revisions and revivals.

**Print Name of Copyright holder:** .....

This will be printed on the copyright line on each page of the Article. It is your responsibility to provide the correct information of the copyright holder.

☐ **BOX C: to be completed if the Article is in the public domain (e.g. US Federal Government employees)** You certify that the Article is in the public domain. No licence to publish is therefore necessary.

**Signature (on behalf of all co-authors (if any))** .....

**Print name:** *Harry Hua Xiang Xia*

**Date:** *8/25/2008*

If your employer claims copyright in your work, this form must also be signed below by a person authorized to sign for and on behalf of your employer, as confirmation that your employer accepts the terms of this licence.

**Signature (on behalf of the employer of the author (s))** .....

**Print name of employer:** .....

**Date:** .....

The rights conveyed in this licence will only apply upon acceptance of your Article for publication.

**Data Protection:** The Publisher may store your name and contact details in electronic format in order to correspond with you about the publication of your Article in the Journal. We would like to contact you from time to time with information about new Blackwell publications and services in your subject area. (For European contributors, this may involve transfer of your personal data outside the European Economic Area.) Please check the following boxes if you are happy to be contacted in this way:

☐ (conventional mailing) ☒ (via e-mail)

Please return the signed form to *Alimentary Pharmacology & Therapeutics*, 49 Carvers Croft, Woolmer Green, Herts SG3 6LX, UK.

26 May 2005

#### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.



### AUTHOR DECLARATION FORM

At submission, **EVERY AUTHOR** listed in the manuscript must **READ** and **COMPLETE** the following statements on: (A) Authorship Responsibility, (B) Authorship Criteria, (C) Authorship Contribution, (D) Funding Disclosures, (E) Contributor Disclosures/Acknowledgments, and (F) Conflicts of Interest Disclosures.

It is important that you return this form as early as possible in the publication process. **EVERY AUTHOR MUST COMPLETE AN INDIVIDUAL COPY OF THE FORM, AND EVERY SECTION OF THE FORM MUST BE COMPLETED.** We will **NOT** publish your manuscript until every author has completed the form and returned it to us.

Your name (please print): Harry H. X. Xia E-mail: xiaharry@hotmail.com  
Journal name: Drug Safety Corresponding author: Weicheng-You  
Manuscript title: The risk of cardiovascular and other adverse events associated with Celecoxib in a two-year trial for gastric cancer prevention

#### A. AUTHORSHIP RESPONSIBILITY

☒ I certify that **BOTH** of the following statements are correct (PLEASE CHECK THE BOX).

- The manuscript represents valid work; neither this manuscript nor one with substantially similar content under my authorship has been published or is being considered for publication elsewhere (except as described in the manuscript submission); and copies of any closely related manuscripts are enclosed in the manuscript submission; **AND**
- For manuscripts with more than one author, I agree to allow the corresponding author to serve as the primary correspondent with the editorial office and to review and sign off on the final proofs prior to publication; or, if I am the only author, I will be the corresponding author and agree to serve in the roles described above.

#### B. AUTHORSHIP CRITERIA

To fulfill all of the criteria for authorship, every author of the manuscript must have made substantial contributions to **ALL** of the following aspects of the work:

- Conception and planning of the work that led to the manuscript or acquisition, analysis and interpretation of the data, or both; **AND**
- Drafting and/or critical revision of the manuscript for important intellectual content; **AND**
- Approval of the final submitted version of the manuscript.

☒ I certify that I fulfill **ALL** of the above criteria for authorship (PLEASE CHECK THE BOX).

#### C. AUTHORSHIP CONTRIBUTION

I certify that I have participated sufficiently in the work to take public responsibility for (PLEASE CHECK 1 OF THE 2 BOXES BELOW):

- ☒ Part of the content of the manuscript; **OR**  
☐ The entire content of the manuscript.

#### D. FUNDING DISCLOSURES

PLEASE CHECK 1 OF THE 2 BOXES BELOW:

- ☒ I certify that no funding has been received for the conduct of this study and/or preparation of this manuscript; **OR**  
☐ I certify that all financial and material support for this work is clearly described in the Acknowledgments section of the manuscript.

#### E. CONTRIBUTOR DISCLOSURES

All persons who have made substantial contributions to the work reported in the manuscript (e.g. data collection, data analysis, or writing or editing assistance) but who do not fulfill the authorship criteria **MUST** be named with their specific contributions in the Acknowledgments section of the manuscript. Groups of persons who have contributed may be listed under a heading such as 'Clinical investigators' and their function descriptor. Because readers may infer their endorsement of the manuscript, all persons named in the Acknowledgments section **MUST** give the authors their written permission to be named in the manuscript.

☒ I certify that all persons who have made substantial contributions to this manuscript but who do not fulfill the authorship criteria are listed with their specific contributions in the Acknowledgments section in the manuscript, and that all persons named in the Acknowledgments section have given me written permission to be named in the manuscript.

#### F. CONFLICT OF INTEREST DISCLOSURES

A conflict of interest exists when professional judgment concerning a primary interest (such as patients' welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). A conflict of interest may arise for

#### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

authors when they have a financial interest that may influence – probably without their knowing – their interpretation of their results or those of others.

We believe that to make the best decision on how to deal with a manuscript we should know about any such conflict of interest that the authors may have. We are not aiming to eradicate conflicts of interests – they are almost inevitable. We will not reject manuscripts simply because the authors have a conflict of interest, but we will publish a declaration in the manuscript as to whether or not the authors have conflicts of interests.

All authors **MUST** complete the following checklist:

Your name (please print): Harry H. X. Xia

Category of potential conflict of interest	If you have had any of the listed relationships with an entity that has a financial interest in the subject matter discussed in this manuscript, please check the appropriate "Yes" box below and provide details. If you do not have a listed relationship, please check the appropriate "No" box. When completing this section, please take into account the past 5 years through to the foreseeable future.		
	No (✓)	Yes (✓)	Details
Employment	✓		
Consultancies	✓		
Honoraria	✓		
Stock ownership options (other than from mutual funds)	✓		
Expert testimony	✓		
Grants received	✓		
Grants pending	✓		
Patents received	✓		
Patents pending	✓		
Royalties	✓		
Other	✓		

Every author **MUST** complete option 1 or option 2 as appropriate below. If you answered "Yes" to any of the questions relating to financial conflicts of interests in the table above (or if you wish to disclose a non-financial conflict of interest), you **MUST** write a suitable statement in the box below. This statement will be published in the Acknowledgments section of the manuscript.

☒ I have no conflicts of interest to declare; **OR**

#### Disclaimer

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

☐ Please insert the following statement regarding conflicts of interest in the Acknowledgments section of the manuscript:

**Declaration:** I certify that I have fully read and fully understood this form, and that the information that I have presented here is accurate and complete to the best of my knowledge.

Your name (please print): Harry H. X. Xia

Signature (please **HAND-WRITE**): Harry H. X. Xia

Date: 7/17/2007

The completed form should be sent by fax to (New Zealand) +64-9-477 0781 or scanned and sent as an email attachment.

---

**Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.

---

## 校样及单行本订单样本(Examples for Proofs and Reprint Order Form)

### 例一 *Alimentary Pharmacology & Therapeutics*



153APT08-ZhangYY-  
HPReinfection.pdf



RepliestoQueries.PD  
F

### 例二 *Cancer*



Proofs&ReprintOrder  
Cancer.pdf

---

#### **Disclaimer**

The templates are prepared by **Medjaden Inc.** ([www.medjaden.com](http://www.medjaden.com), [medjaden@gmail.com](mailto:medjaden@gmail.com)) as references, for our fellow Chinese investigators to publish their research articles in English journals. **Medjaden** encourages authors to use the templates in a creative way because the situation of every article is unique and is different from each other. Copy/paste of this template without consideration of the unique nature of the article may lead to the rejection of the article. **Medjaden** is not responsible, in any way, for any negative decision made by the journals.